Target Name: WIPF1
NCBI ID: G7456
Review Report on WIPF1 Target / Biomarker Content of Review Report on WIPF1 Target / Biomarker
WIPF1
Other Name(s): PRPL-2 | testicular tissue protein Li 226 | PRPL-2 protein | WAS/WASL-interacting protein family member 1 (isoform a) | WAS/WASL interacting protein family member 1, transcript variant 1 | WASPIP | WIP | WAS/WASL-interacting protein family member 1 | WAS2 | WASP-interacting protein | WIPF1_HUMAN | Wiskott-Aldrich syndrome protein-interacting protein | Wiskott-Aldrich syndrome protein interacting protein | WIPF1 variant 1 | protein PRPL-2 | WAS/WASL interacting protein family member 1 | Protein PRPL-2

WIPF1: A Protein Target for Tissue Maintenance and Disease

WIPF1 (PRPL-2) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of the protein beta-protein selectin (BPS), which is involved in the development and maintenance of tight junctions, which are a type of cell-cell barrier.

Recent studies have identified WIPF1 as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because WIPF1 plays a role in the regulation of cell-cell interactions, which can be disrupted in these conditions.

One of the reasons for the potential of WIPF1 as a drug target is its involvement in the regulation of cell-cell adhesion. This is important for the development and maintenance of tissues and organs, as well as for the regulation of various physiological processes, such as blood flow and inflammation.

WIPF1 is also involved in the regulation of cell-cell interactions in the developing nervous system. During development, WIPF1 helps to ensure that neurons and glial cells stick together to form the neural tube, which eventually forms the brain and spinal cord.

In addition to its role in cell-cell interactions, WIPF1 is also involved in the regulation of cell-cell signaling pathways. This includes the regulation of the protein T-cell factor (TGF-), which is important for the development and maintenance of tissues and organs, as well as for the regulation of immune responses.

The potential of WIPF1 as a drug target is based on its involvement in the regulation of cell-cell interactions and signaling pathways. This makes it a promising target for the development of new treatments for a variety of diseases.

In conclusion, WIPF1 (PRPL-2) is a protein that is involved in the regulation of cell-cell interactions and signaling pathways. Its potential as a drug target is based on its involvement in the development and maintenance of tissues and organs, as well as its role in the regulation of various physiological processes. Further research is needed to fully understand the potential of WIPF1 as a drug target for the treatment of various diseases.

Protein Name: WAS/WASL Interacting Protein Family Member 1

Functions: Plays a role in the reorganization of the actin cytoskeleton. Contributes with NCK1 and GRB2 in the recruitment and activation of WASL. May participate in regulating the subcellular localization of WASL, resulting in the disassembly of stress fibers in favor of filopodia formation. Plays a role in the formation of cell ruffles (By similarity). Plays an important role in the intracellular motility of vaccinia virus by functioning as an adapter for recruiting WASL to vaccinia virus

The "WIPF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WIPF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

WIPF2 | WIPF3 | WIPI1 | WIPI2 | WIZ | WLS | WNK1 | WNK2 | WNK3 | WNK4 | Wnt | WNT1 | WNT10A | WNT10B | WNT11 | WNT16 | WNT2 | WNT2B | WNT3 | WNT3A | WNT4 | WNT5A | WNT5B | WNT6 | WNT7A | WNT7B | WNT8A | WNT8B | WNT9A | WNT9B | WRAP53 | WRAP73 | WRN | WRNIP1 | WSB1 | WSB2 | WSCD1 | WSCD2 | WSPAR | WT1 | WT1-AS | WTAP | WTAPP1 | WTIP | WWC1 | WWC2 | WWC2-AS2 | WWC3 | WWOX | WWP1 | WWP2 | WWTR1 | WWTR1-AS1 | XAB2 | XACT | XAF1 | XAGE-4 | XAGE1A | XAGE1B | XAGE1D | XAGE2 | XAGE3 | XAGE5 | XBP1 | XCL1 | XCL2 | XCR1 | XDH | XG | XGY2 | XIAP | XIRP1 | XIRP2 | XIST | XK | XKR3 | XKR4 | XKR5 | XKR6 | XKR7 | XKR8 | XKR9 | XKRX | XKRY | XKRYP7 | XLOC_007697 | XLOC_008559 | XLOC_009911 | XNDC1N | XPA | XPC | XPC complex | XPNPEP1 | XPNPEP2 | XPNPEP3 | XPO1 | XPO4 | XPO5 | XPO6 | XPO7